Rituximab long-term maintenance therapy after autologous stem cell transplantation in patients with B-cell non-Hodgkin's lymphoma

Annals of Hematology
Frank NeumannGuido Kobbe

Abstract

Treatment of B-cell non-Hodgkin's lymphomas (NHL) with either Rituximab alone or in combination with cytotoxic chemotherapy has been effective without major side effects. Thus, Rituximab maintenance therapy after autologous peripheral blood stem cell transplantation (PBSCT) might represent an improvement in NHL therapy. We therefore retrospectively analyzed the efficacy and side effects of monthly long-term Rituximab maintenance therapy after PBSCT in 27 patients with NHL. In median 10 infusions of Rituximab were given after PBSCT in time intervals of 1 month. Molecular monitoring of t(14;18) was performed using nested as well as quantitative real time polymerase chain reaction (RT-PCR) based on the LightCycler technology. Side effects according to common toxicity criteria (CTC) > II did mainly affect the hematopoietic system. In total, 10 patients (37%) suffered form grade III-IV hematotoxicity. Except for two patients with cutaneous Varicella-Zoster infection no serious infectious complications (CTC grade III/IV) occurred. No patient died because of treatment-related causes. This adverse event data compared favorably to the published data. Three patients had t(14;18) nested RT-PCR positive results before Rituximab therapy and...Continue Reading

References

Aug 12, 1999·Annals of Oncology : Official Journal of the European Society for Medical Oncology·L D PiroV Jain
Apr 17, 2001·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·J C ByrdI W Flinn
Apr 17, 2001·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·S M O'BrienM J Keating
Jan 25, 2002·The New England Journal of Medicine·Bertrand CoiffierChristian Gisselbrecht
Mar 1, 2002·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Orion M HowardMargaret A Shipp
Oct 16, 2002·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·John D HainsworthF Anthony Greco
Mar 27, 2004·The New England Journal of Medicine·Noel MilpiedUNKNOWN Groupe Ouest-Est des Leucémies et des Autres Maladies du Sang
Dec 16, 2004·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Michele GhielminiUNKNOWN Swiss Group for Clinical Cancer Research
Feb 1, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·M S CzuczmanS H Bernstein
May 24, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Mathias J RummelParis S Mitrou

❮ Previous
Next ❯

Citations

May 29, 2007·Oncogene·B Coiffier
Jan 1, 2010·ClinicoEconomics and Outcomes Research : CEOR·Firas Badin, John Hayslip
Apr 29, 2009·Leukemia & Lymphoma·Ron RamPia Raanani
Jun 11, 2011·Best Practice & Research. Clinical Haematology·Andrew R Rezvani, David G Maloney
Apr 3, 2008·Seminars in Hematology·Alden Moccia, Michele Ghielmini
Sep 12, 2014·Annals of Medicine·Mehdi Hamadani
Oct 10, 2012·Hematological Oncology·Amruth R Palla, Mehdi Hamadani
Mar 7, 2007·Expert Review of Anticancer Therapy·Bridgette Collins-Burow, Edgardo S Santos

❮ Previous
Next ❯

Related Concepts

Related Feeds

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.

Cancer Stem Cells in Glioblastoma

Glioblastoma is the most common and aggressive type of brain tumor. It contains a population of tumor initiating stem cell-like cells known as cancer stem cells. Investigations are ongoing into these cancer stem cells found in these solid tumors which are highly resistance to treatment. Here is the latest research on cancer stem cells in glioblastoma.

B-Cell Lymphoma

B-cell lymphomas include lymphomas that affect B cells. This subtype of cancer accounts for over 80% of non-Hodgkin lymphomas in the US. Here is the latest research.